- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00716859
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
1 februari 2021 bijgewerkt door: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
139
Fase
- Fase 3
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Leuven, België, 3000
- Pfizer Investigational Site
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 0000
- Pfizer Investigational Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 0000
- Pfizer Investigational Site
-
-
-
-
-
Regenstauf, Duitsland, 93128
- Pfizer Investigational Site
-
Schorndorf, Duitsland, 73614
- Pfizer Investigational Site
-
-
-
-
-
Makati City, Filippijnen, 1200
- Pfizer Investigational Site
-
Mandaluyong City, Filippijnen, 1500
- Pfizer Investigational Site
-
-
-
-
-
Lille Cedex, Frankrijk, 59037
- Pfizer Investigational Site
-
Lyon, Frankrijk, 69437
- Pfizer Investigational Site
-
-
Cedex 1
-
Amiens, Cedex 1, Frankrijk, 80054
- Pfizer Investigational Site
-
-
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, Indië, 500034
- Pfizer Investigational Site
-
-
Gujarat
-
Ahmedabad, Gujarat, Indië, 380004
- Pfizer Investigational Site
-
-
Tamilnadu
-
Coimbatore, Tamilnadu, Indië, 641 014
- Pfizer Investigational Site
-
-
-
-
-
Catania, Italië, 95123
- Pfizer Investigational Site
-
Milano, Italië, 20162
- Pfizer Investigational Site
-
-
-
-
-
Kharkiv, Oekraïne, 61000
- Pfizer Investigational Site
-
Kyiv, Oekraïne
- Pfizer Investigational Site
-
Kyiv, Oekraïne, 04050
- Pfizer Investigational Site
-
Kyiv, Oekraïne, 01135
- Pfizer Investigational Site
-
Odesa, Oekraïne, 65061
- Pfizer Investigational Site
-
-
-
-
-
Bialystok, Polen, 15-274
- Pfizer Investigational Site
-
Gdansk, Polen, 80-211
- Pfizer Investigational Site
-
Wroclaw, Polen, 50-368
- Pfizer Investigational Site
-
-
-
-
-
Coimbra, Portugal, 3000-548
- Pfizer Investigational Site
-
Lisboa, Portugal, 1649-035
- Pfizer Investigational Site
-
Lisboa, Portugal, 1169-019
- Pfizer Investigational Site
-
Lisboa, Portugal, 1169-097
- Pfizer Investigational Site
-
Porto, Portugal, 4099-001
- Pfizer Investigational Site
-
-
-
-
Cluj
-
Cluj-Napoca, Cluj, Roemenië, 400006
- Pfizer Investigational Site
-
-
-
-
-
Moscow, Russische Federatie, 119331
- Pfizer Investigational Site
-
St. Petersburg, Russische Federatie, 194100
- Pfizer Investigational Site
-
-
-
-
-
Belgrade, Servië, 11000
- Pfizer Investigational Site
-
-
-
-
-
Ljubljana, Slovenië, 1000
- Pfizer Investigational Site
-
-
-
-
-
Bratislava, Slowakije, 83340
- Pfizer Investigational Site
-
-
-
-
-
Madrid, Spanje, 28040
- Pfizer Investigational Site
-
Sevilla, Spanje, 41013
- Pfizer Investigational Site
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spanje, 08950
- Pfizer Investigational Site
-
-
-
-
-
Praha 5, Tsjechië, 150 06
- Pfizer Investigational Site
-
-
-
-
-
Birmingham, Verenigd Koninkrijk, B18 7QH
- Pfizer Investigational Site
-
London, Verenigd Koninkrijk, EC1V 2PD
- Pfizer Investigational Site
-
-
-
-
Florida
-
Pembroke Pines, Florida, Verenigde Staten, 33028
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Pfizer Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- Pfizer Investigational Site
-
-
Nevada
-
Henderson, Nevada, Verenigde Staten, 89052
- Pfizer Investigational Site
-
Henderson, Nevada, Verenigde Staten, 89074
- Pfizer Investigational Site
-
Las Vegas, Nevada, Verenigde Staten, 89148
- Pfizer Investigational Site
-
-
-
-
-
Myfair West, Zuid-Afrika, 2109
- Pfizer Investigational Site
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
8 maanden tot 18 jaar (Kind, Volwassen)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Male or female of 18 years of age or under
- Diagnosis of glaucoma
- IOP of 22 mmHg or above in at least 1 eye
Exclusion Criteria:
- Require surgery for acute angle closure
- Have had prior cyclodestructive procedures
- Have a history of ocular trauma or surgery in either eye within 3 months of the baseline visit
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Timolol
|
Timolol 0.5% dosed twice-daily
|
Experimenteel: latanoprost
|
Latanoprost 0.005% ophthalmic solution dosed once-daily
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)
Tijdsspanne: Baseline, Week 12
|
Calculated as Baseline IOP minus Week 12 IOP, LOCF.
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were less than or equal to (≤) 2 millimeters of mercury (mmHg) of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Reduction From Baseline in Mean IOP at Week 1
Tijdsspanne: Baseline, Week 1
|
Calculated as Baseline IOP minus Week 1 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 1
|
Reduction From Baseline in Mean IOP at Week 4
Tijdsspanne: Baseline, Week 4
|
Calculated as Baseline IOP minus Week 4 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 4
|
Reduction From Baseline in Mean IOP at Week 12 (Observed)
Tijdsspanne: Baseline, Week 12
|
Calculated as Baseline IOP minus Week 12 IOP (observed).
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 12
|
Mean IOP at Baseline
Tijdsspanne: Baseline
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline
|
Mean IOP at Week 1
Tijdsspanne: Week 1
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 1
|
Mean IOP at Week 4
Tijdsspanne: Week 4
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 4
|
Mean IOP at Week 12
Tijdsspanne: Week 12
|
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Week 12
|
Percentage of Participants With Greater Than or Equal to (≥) 15% IOP Reduction From Baseline at Both Weeks 4 and 12
Tijdsspanne: Baseline, Week 4, and Week 12
|
Participants with ≥15% IOP reduction from baseline at both Week 4 and Week 12. Calculated as (post baseline IOP minus baseline IOP) divided by IOP, multiplied by 100%.
IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen.
IOP was measured twice and if the measurements were ≤ 2 mmHg of each other, the mean of the 2 readings was recorded as the IOP at that time point.
Otherwise, a third IOP measurement was taken and the median IOP recorded.
|
Baseline, Week 4, and Week 12
|
Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience
Tijdsspanne: Baseline through Week 12
|
An investigator's causality assessment was the determination of whether there existed a reasonable possibility that the investigational product caused or contributed to an adverse event (AE).
If the investigator did not know whether or not investigational product caused the event, then the event was handled as "related to investigational product" for reporting purposes.
|
Baseline through Week 12
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 juli 2008
Primaire voltooiing (Werkelijk)
1 november 2009
Studie voltooiing (Werkelijk)
1 november 2009
Studieregistratiedata
Eerst ingediend
14 juli 2008
Eerst ingediend dat voldeed aan de QC-criteria
14 juli 2008
Eerst geplaatst (Schatting)
16 juli 2008
Updates van studierecords
Laatste update geplaatst (Werkelijk)
3 februari 2021
Laatste update ingediend die voldeed aan QC-criteria
1 februari 2021
Laatst geverifieerd
1 januari 2011
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Oogziekten
- Oculaire hypertensie
- Glaucoom
- Fysiologische effecten van medicijnen
- Adrenerge beta-antagonisten
- Adrenerge antagonisten
- Adrenerge middelen
- Neurotransmitter agenten
- Moleculaire mechanismen van farmacologische werking
- Middelen tegen aritmie
- Antihypertensiva
- Farmaceutische oplossingen
- Oogheelkundige oplossingen
- Timolol
- Latanoprost
Andere studie-ID-nummers
- A6111137
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Glaucoom
-
Hillel Yaffe Medical CenterOnbekend
-
Inonu UniversityVoltooidGLAUCOMA 1, OPEN HOEK, D (aandoening)Kalkoen
Klinische onderzoeken op Timolol
-
Laboratoires TheaVoltooidOculaire hypertensie GlaucoomBulgarije
-
ForSight Vision5, Inc.VoltooidOculaire hypertensie | OpenkamerhoekglaucoomPanama
-
Afyon Kocatepe University HospitalVoltooid
-
Medical University of ViennaVoltooid
-
Aristotle University Of ThessalonikiVoltooidOpenkamerhoekglaucoomGriekenland
-
Santen OyVoltooidOculaire hypertensie | OpenkamerhoekglaucoomHongarije
-
Alcon ResearchVoltooidOculaire hypertensie | Openkamerhoekglaucoom
-
Aristotle University Of ThessalonikiVoltooid
-
AllerganVoltooidOculaire hypertensie | Glaucoom, open hoekVerenigde Staten, Singapore, Italië, Verenigd Koninkrijk, Egypte, Korea, republiek van, Argentinië, Canada, Colombia, Tsjechië, Duitsland, Maleisië, Nieuw-Zeeland, Zuid-Afrika, Kalkoen